Reata Pharma (RETA) Tops Q1 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
May 6, 2021 6:45 AM EDTANNOUNCES FDA ACCEPTED FOR FILING REATAS NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME
IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT SYNDROME, A LIFE-THREATENING DISEASE THAT AFFECTS 30,000 60,000 PATIENTS IN THE U.S.
REAFFIRMS ANTICIPATED COMPLETION OF ENROLLMENT BY END OF 2021 IN PHASE 3 FALCON TRIAL FOR ADPKD
FDA GRANTED TYPE C MEETING TO DISCUSS FA DEVELOPMENT PROGRAM IN 2Q 2021
CONFIRMS CASH RUNWAY THROUGH... More
